Liquid oral composition

Abstract

The purpose of the present invention is to provide a liquid composition for the oral cavity, which contains glycyrrhizic acid and potassium nitrate, can exert a hypersensitive effect and mask the salty taste / unpleasant taste of potassium nitrate, and in which the stability of the glycyrrhizic acid salt is good. The present invention provides a liquid oral composition containing: (A) glycyrrhizic acid, or a salt such as a sodium salt, a potassium salt, or an ammonium salt of glycyrrhizic acid; (B) inorganic water-soluble potassium salts such as potassium nitrate and potassium fluoride; and (C) a pyrrolidone carboxylate salt such as a sodium pyrrolidone carboxylate, a calcium pyrrolidone carboxylate, a magnesium pyrrolidone carboxylate, a zinc pyrrolidone carboxylate, or a potassium pyrrolidone carboxylate.

Description

Technical Field

[0001] The present invention relates to liquid oral compositions. Background Art

[0002] As a preventive measure for dentin hypersensitivity, it is known to mix potassium nitrate, which has a nerve numbing effect and is known as an effective ingredient for preventing hyperesthesia, into an oral composition (for example, Patent Document 1). Potassium nitrate has a unique salty / unpleasant taste, and it is desirable to alleviate this salty / unpleasant taste, especially in the use of mouthwashes.

[0003] In addition, various active ingredients are mixed in oral compositions for the purpose of preventing / treating adverse conditions in the oral cavity. In particular, in the prevention / treatment of periodontal diseases, various active ingredients having inflammation-suppressing effects, blood circulation-promoting effects, tissue activation effects, etc. are used. Among them, glycyrrhizic acid and its salts are widely used because they are active ingredients derived from natural products and have high anti-inflammatory effects. In addition, glycyrrhizic acid and its salts have a sweetness 100 to 200 times that of sucrose and are also used as high-intensity sweeteners.

[0004] On the other hand, it is also reported that oral compositions containing pyrrolidone carboxylic acid can exert anti-inflammatory effects, formulation stability and other effects (for example, Patent Document 2). Patent Document 3 records that a liquid oral composition containing pyrrolidone carboxylic acid, a monovalent to trivalent metal ion source such as potassium nitrate, a compound having a LogPow value of 1 or more such as vitamin E, a water-soluble polymer compound, and an N-acyl sarcosinate has good appearance stability after high-temperature storage. [Prior art literature] [Patent Document]

[0005] [Patent Document 1] JP-A-2016-150912 [Patent Document 2] International Publication No. WO2014 / 157547 [Patent Document 3] International Publication No. WO2021 / 132169 Summary of the invention [Problems to be solved by the invention]

[0006] When glycyrrhizic acid and potassium nitrate are combined in liquid oral compositions such as mouthwashes in an attempt to mask the unique salty / unpleasant taste of potassium nitrate, there is room for improvement in the stability of glycyrrhizic acid salts (dispersibility in the preparation).

[0007] The present invention has been made in view of the above, and an object of the present invention is to provide a liquid oral composition containing glycyrrhizic acid and potassium nitrate, which can exert a hyperesthesia effect to mask the salty / unpleasant taste of potassium nitrate and has good stability of glycyrrhizic acid salt. [Methods used to solve the problem]

[0008] The present invention provides the following [1] to

[10] . [1] A liquid oral composition comprising: (A) glycyrrhizic acid or its salt, (B) Inorganic water-soluble potassium salts and (C) Pyrrolidone carboxylate. [2] The liquid oral composition according to [1], wherein the component (A) is one or more selected from the group consisting of sodium salts, potassium salts, and ammonium salts of glycyrrhizic acid. [3] The liquid oral composition according to [1] or [2], wherein the component (B) is one or more selected from potassium nitrate and potassium fluoride. [4] The liquid oral composition according to any one of [1] to [3], wherein the component (C) is one or more selected from pyrrolidone carboxylates, and the pyrrolidone carboxylates are selected from sodium pyrrolidone carboxylate, calcium pyrrolidone carboxylate, magnesium pyrrolidone carboxylate, zinc pyrrolidone carboxylate, and potassium pyrrolidone carboxylate. [5] The liquid oral composition according to any one of [1] to [4], wherein the content of the component (A) is 0.001 to 2% by mass. [6] The liquid oral composition according to any one of [1] to [5], wherein the content of the component (B) is 0.1 to 10% by mass. [7] The liquid oral composition according to any one of [1] to [6], wherein the content of the component (C) is 0.1 to 20% by mass as the amount of pyrrolidone carboxylic acid. [8] The liquid oral composition according to any one of [1] to [7], wherein the ratio (B) / (A) of the content of the component (B) to the content of the component (A) is 0.1 to 5000. [9] The liquid oral composition according to any one of [1] to [8], wherein the ratio (C) / (B) of the content of the component (C) to the content of the component (B) is 0.01 to 200.

[10] The liquid oral composition according to any one of [1] to [9], wherein the ratio (C) / (A) of the content of the component (C) to the content of the component (A) is 0.1 to 10,000. [Effects of the Invention]

[0009] According to the present invention, there can be provided a liquid oral composition which can exert a hyperesthesia suppressing effect, has a good feeling during use by masking a salty / unpleasant taste, and has excellent stability due to good dispersibility of glycyrrhizic acid. DETAILED DESCRIPTION

[0010] [1. Liquid oral composition] The liquid oral composition contains (A) to (C) components.

[0011] [(A) ingredient] The component (A) is glycyrrhizic acid or a salt thereof. By containing glycyrrhizic acid or a salt thereof, an anti-inflammatory effect can be exhibited.

[0012] As the salt of glycyrrhizic acid, for example, alkali metal salts such as sodium salts and potassium salts and ammonium salts can be mentioned, preferably sodium salts, potassium salts, ammonium salts, and more preferably potassium salts. More specifically, for example, disodium glycyrrhizinate, trisodium glycyrrhizinate, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate can be mentioned, preferably dipotassium glycyrrhizinate. Glycyrrhizic acid or its salts can be derived from natural raw materials such as plants, or can be industrially produced. (A) Component may be one selected from glycyrrhizic acid and salts thereof, or may be a combination of two or more.

[0013] The content of component (A) in the liquid oral composition is preferably 0.002% by mass or more, more preferably 0.005% by mass or more. Thus, the anti-inflammatory effect can be fully exerted. The upper limit is preferably 1% by mass or less, more preferably 0.75% by mass or less. Thus, rapid dispersion of component (A) in the liquid preparation can be achieved. Therefore, the content of component (A) is preferably 0.002 to 1% by mass, more preferably 0.005 to 0.75% by mass.

[0014] [(B) ingredient] The component (B) is an inorganic water-soluble potassium salt. The inclusion of an inorganic water-soluble potassium salt can exert an effect of suppressing hyperesthesia.

[0015] Examples of the inorganic water-soluble potassium salt include potassium nitrate and potassium fluoride, preferably potassium nitrate. The inorganic water-soluble potassium salt may be derived from natural raw materials such as plants, or may be industrially produced. Component (B) may be one inorganic water-soluble potassium salt, or may be a combination of two or more inorganic water-soluble potassium salts.

[0016] The content of component (B) in the liquid oral composition is preferably 0.1% by mass or more, more preferably 1% by mass or more. Thus, the hyperesthesia inhibitory effect can be fully exerted. The upper limit is preferably 10% by mass or less, more preferably 6% by mass or less. Thus, the generation of the unique salty / unpleasant taste from component (B) can be suppressed, and masking based on other ingredients can be achieved. Therefore, the content of component (B) is preferably 0.1 to 10% by mass, more preferably 1 to 6% by mass.

[0017] [(C) ingredient] The component (C) is a pyrrolidone carboxylate. By containing a pyrrolidone carboxylate, a root caries preventive effect can be exhibited, and a salty / unpleasant taste and stability can be improved.

[0018] Pyrrolidone carboxylates are usually inorganic salts, for example, alkali metal salts such as sodium pyrrolidone carboxylate and potassium pyrrolidone carboxylate, alkaline earth metal salts such as calcium pyrrolidone carboxylate and magnesium pyrrolidone carboxylate, and zinc pyrrolidone carboxylate. Among them, sodium pyrrolidone carboxylate is preferred. Pyrrolidone carboxylates may be derived from natural raw materials such as plants, or may be industrially manufactured. (C) component may be one pyrrolidone carboxylate, or may be a combination of two or more pyrrolidone carboxylates.

[0019] The content of component (C) in the liquid oral composition (the amount of pyrrolidone carboxylic acid (excluding the amount of salt), the same below) is preferably 0.1% by mass or more, more preferably 2% by mass or more. Thus, the compounding effect of component (C) can be fully exerted. The upper limit is usually 25% by mass or less, preferably 20% by mass or less, and more preferably 18% by mass or less. Thus, the above-mentioned effects can be exerted, and the generation of a unique flavor from component (C) can be suppressed by a further preferred amount or less. Therefore, the content of component (C) is preferably 0.1 to 20% by mass, more preferably 2 to 18% by mass.

[0020] [(B) / (A)] The ratio (B) / (A) of the content of the component (B) to the content of the component (A) is preferably 0.1 or more, more preferably 0.12 or more. In addition, the upper limit is preferably 5000 or less, more preferably 4800 or less. Therefore, (B) / (A) is preferably 0.1 to 5000, more preferably 0.12 to 4800.

[0021] [(C) / (B)] The ratio (C) / (B) of the content of the component (C) to the content of the component (B) is preferably 0.01 or more, more preferably 0.012 or more. In addition, the upper limit is preferably 200 or less. Therefore, (C) / (B) is preferably 0.01 to 200, more preferably 0.012 to 200.

[0022] [(C) / (A)] The ratio (C) / (A) of the content of the component (C) to the content of the component (A) is preferably 0.1 or more, more preferably 0.12 or more. In addition, the upper limit is preferably 10000 or less, more preferably 9500 or less. Therefore, (C) / (A) is preferably 0.1 to 10000, more preferably 0.12 to 9500.

[0023] [Optional Ingredients] The liquid oral composition may contain appropriate known ingredients as needed in addition to the above-mentioned (A) to (C) components, depending on the dosage form and purpose of use described later. For example, surfactants, thickeners, preservatives, sweeteners, wetting agents, colorants, flavors, pH adjusters, active ingredients, and solvents may be mentioned. When the liquid oral composition is a mouthwash, it usually does not contain insoluble solid components such as abrasives.

[0024] Examples of the surfactant include nonionic surfactants, amphoteric surfactants, and anionic surfactants.

[0025] Examples of nonionic surfactants include polyoxyethylene alkyl ethers (e.g., polyoxyethylene cetyl ether), polyoxyethylene hydrogenated castor oil, sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monostearate), alkylolamides, polyoxyethylene fatty acid esters, polyoxyethylene alkenyl ethers, glycerol fatty acid esters, sucrose fatty acid esters (e.g., maltose fatty acid esters), sugar alcohol fatty acid esters (e.g., maltitol fatty acid esters, lactitol fatty acid esters), fatty acid diethanolamides (e.g., lauric acid mono- or diethanolamide), polyoxyethylene polyoxypropylene copolymers, and polyoxyethylene polyoxypropylene fatty acid esters. The number of carbon atoms in the alkyl chain of the polyoxyethylene alkyl ether is usually 14 to 18, and the average number of ethylene oxide added is usually 15 to 30 mol. The average number of ethylene oxide added to the polyoxyethylene hydrogenated castor oil is usually 20 to 100 mol, preferably 60 to 100 mol. The carbon number of the fatty acid in the sorbitan fatty acid ester is usually 12 to 18. The carbon number of the fatty acid in the polyoxyethylene sorbitan fatty acid ester is usually 16 to 18, and the average number of moles of ethylene oxide added is usually 10 to 40. The carbon number of the alkyl chain of the alkylolamide is usually 12 to 14. As the nonionic surfactant, polyoxyethylene hydrogenated castor oil is preferred.

[0026] Examples of the amphoteric surfactant include betaine-type surfactants such as alkyldimethylaminoacetic acid betaine and fatty acid amidepropyldimethylaminoacetic acid betaine.

[0027] As anionic surfactants, for example, alkyl sulfates, acyl amino acid salts, acyl taurates, α-olefin sulfonates, hydrogenated coconut fatty acid monoglyceride monosulfate, and alkyl sulfoacetates can be cited. In the case of an alkyl group, the alkyl group can be any of a straight chain and a branched chain, and can be any of saturated and unsaturated, and the number of carbon atoms is usually 12 to 14. In the case of an acyl group, the acyl group can be any of a straight chain or a branched chain, and can be any of saturated and unsaturated, and the number of carbon atoms is usually 10 to 20. The salt can be selected from pharmacologically acceptable salts. As pharmacologically acceptable salts, for example, inorganic base salts such as sodium salts, potassium salts, calcium salts, magnesium salts, and ammonium salts; organic base salts such as triethylammonium salts, triethanolammonium salts, pyridinium salts, and diisopropylammonium salts; basic amino acid salts such as arginine salts, lysine salts, and histidine salts can be cited. Among them, inorganic base salts are preferred, alkali metal salts (eg, sodium salts, potassium salts) or ammonium salts are more preferred, and sodium salts are further preferred.

[0028] Examples of the alkyl sulfate include lauryl sulfate and myristyl sulfate. Examples of the acyl amino acid salt include acyl sarcosinates such as lauroyl sarcosinate and myristoyl sarcosinate; acyl glutamates such as lauroyl glutamate, myristoyl glutamate, and palmitoyl glutamate; acyl glycinates such as N-lauroyl-N-methyl glycinate and cocoyl glycinate; acyl alaninates such as N-lauroyl-β-alaninate, N-myristoyl-β-alaninate, N-cocoyl-β-alaninate, N-lauroyl-N-methyl-β-alaninate, N-myristoyl-N-methyl-β-alaninate, and N-methyl-N-acyl alaninate; and acyl aspartate such as lauroyl aspartate. Examples of acyl taurates include lauroyl methyl taurate, N-methyl-N-acyl taurate, and N-cocoyl methyl taurate. Examples of α-olefin sulfonates include α-olefin sulfonates having 12 to 14 carbon atoms, such as tetradecene sulfonate. Other examples of anionic surfactants include sodium hydrogenated coconut oil fatty acid monoglyceride monosulfate and sodium lauryl sulfoacetate.

[0029] When the liquid oral composition contains the above-mentioned surfactant, the total content of the surfactant is preferably 0.05 to 2.0%, more preferably 0.1 to 1.5%.

[0030] Examples of the thickener include cellulose compounds such as sodium carboxymethylcellulose and gums such as xanthan gum. When the liquid oral composition contains a thickener, the content thereof is usually 0 to 3%.

[0031] Examples of the preservative include p-hydroxybenzoic acid esters, benzoic acid, or a sodium salt thereof.

[0032] Examples of the sweetener include saccharin sodium and sucralose.

[0033] Examples of the wetting agent include polyols, such as sorbitol, erythritol, maltitol, lactitol, xylitol, and other sugar alcohols; glycerol; glycols such as ethylene glycol, polyethylene glycol (molecular weight 200 to 6000), and propylene glycol; and reduced starch saccharides.

[0034] As the colorant, water-soluble pigments are preferred from the viewpoint of high safety, for example, blue No. 1, green No. 3, yellow No. 4, and red No. 105 can be cited.

[0035] As the fragrance, for example, various fragrance components and essential oils can be mentioned. Specifically, for example, menthol, carvone, anise alcohol, eucalyptol, methyl salicylate, cinnamaldehyde, eugenol, 3-1-menthoxy-1,2-propanediol, thymol, linalool, linalyl acetate, limonene, menthone, menthyl acetate, N-substituted-p-menthane-3-carboxamide, pinene, octanal, citral, pulegone, carvyl acetate, anisaldehyde, ethyl acetate, ethyl butyrate, allyl cyclohexanepropionate, methyl anthranilate, ethyl methylphenyl glycidate, vanillin, undecanoic acid lactone, hexanal, isopentanol, hexenol, dimethyl Thioether, methylcyclopentenol ketone, furfural, trimethylpyrazine, ethyl lactate, methyl lactate, ethyl thioacetate and other fragrance ingredients; peppermint oil, spearmint oil, fennel oil, eucalyptus oil, wintergreen oil, cinnamon oil, clove oil, thyme oil, sage oil, lemon oil, orange oil, mint oil, cardamom oil, coriander oil, tangerine oil, lime oil, lavender oil, rosemary oil, laurel oil, chamomile oil, caraway oil, marjoram oil, bay leaf oil, lemongrass oil, oregano oil, pine needle oil, neroli oil, rose oil, jasmine oil, iris oil, mint absolute, rose absolute, orange blossom (orange The invention also includes natural flavors such as citrus fruit, citrus fruit, and flavors obtained by processing these natural flavors (pre-distillation cutting, post-distillation cutting, fractionation, liquid-liquid extraction, etc.); blended flavors such as strawberry flavor, apple flavor, banana flavor, pineapple flavor, grape flavor, mango flavor, butter flavor, milk flavor, mixed fruit flavor, and tropical fruit flavor. When the liquid oral composition contains flavors, the content of the flavors is usually 0.00001 to 3%.

[0036] Regarding the pH of the liquid oral composition, the pH at 25°C is preferably 5 or more, more preferably 5.5 or more. Thereby, the gelation of the liquid oral composition can be sufficiently suppressed. Regarding the upper limit, the pH at 25°C is preferably 7.7 or less, more preferably 8 or less. Thereby, the appearance stability becomes better. Therefore, regarding the pH of the liquid oral composition, the pH at 25°C is preferably 5 to 8, more preferably 5.5 to 7.5. In order to adjust the pH, a combination of sodium dihydrogen phosphate and sodium monohydrogen phosphate, or a combination of citric acid and sodium citrate may be contained as a pH adjuster.

[0037] Examples of the active ingredient include bactericidal or antibacterial agents such as cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride, zinc gluconate, zinc citrate, triclosan, thymol, hinokitiol, lysozyme chloride, isopropylmethylphenol, and the like; enzymes such as dextranase, mutanase, amylase, protease, lytic enzyme, and the like; fluorides other than potassium fluoride such as sodium fluoride, sodium monofluorophosphate, and tin fluoride; ε-aminocaproic acid, allantoin, tranexamic acid, glycyrrhetinate, aluminum chlorohydroxybutyrate, and the like. allantoinate), azulene, dihydrocholesterol and other anti-inflammatory agents; metal salts such as zinc salts, copper salts, tin salts and other metal salts; condensed phosphates, ethane hydroxy diphosphonates, zeolites and other dental calculus preventives; sensory hypersensitivity inhibitors other than potassium nitrate such as aluminum lactate and strontium chloride; coating agents such as hydroxyethyl cellulose dimethyl diallyl ammonium chloride; astringents such as sodium chloride, aluminum closa, vitamins (e.g., vitamin C, vitamin E), lysozyme chloride, glycyrrhetinic acid and its salts; water-soluble copper compounds such as chlorophyllin copper and copper gluconate; amino acids such as alanine, glycine, and proline; plant extracts; carropeptide, polyvinyl pyrrolidone, and dental calculus preventives. The content of the active ingredient can be appropriately set to an effective amount.

[0038] As the solvent, for example, purified water, ethanol and other lower monohydric alcohols can be cited. When the liquid oral composition contains a lower monohydric alcohol (e.g., ethanol), its content is preferably 10% or less, preferably 5% or less, more preferably substantially not contained (e.g., below the detection limit), and further preferably not contained.

[0039] [2.Purpose] The liquid oral composition can be prepared and used as a concentrated or liquid mouthwash, a liquid dentifrice, a mouth freshener, or the like, and among them, a mouthwash is preferred. [Example]

[0040] The present invention is described below by way of examples. The following examples are not intended to limit the present invention.

[0041] Examples 1 to 31 and Comparative Examples 1 to 3 Liquid oral compositions (mouthwashes) having the compositions described in the following table were prepared according to a conventional method and the following evaluations were performed.

[0042] [Evaluation method] <Evaluation of hyperesthesia reduction effect> Three people with hyperesthesia who felt temporary pain when rinsing their mouths with water after brushing their teeth were selected as subjects. The liquid oral composition was used in the usual mouthwash method, and the pain degree after spitting out was scored based on the following scoring criteria (1 to 4 points), and the hyperesthesia reduction effect was evaluated based on the average of the scores of the three people. It should be noted that the degree of pain before the start of the test was 1 point for all subjects based on the following scoring criteria.

[0043] (Pain severity rating scale) 4 points: No pain 3 points: Almost no pain. 2 points: Feeling slight pain 1 point: Feeling quite painful

[0044] (Evaluation criteria for pain relief effect) ◎: 3.5 points or more and 4.0 points or less ○: 3.0 points or more and less than 3.5 points △: 2.0 points or more and less than 3.0 points ×: Less than 2.0 points

[0045] <Verification of the effect of suppressing unpleasant taste / salty taste> The evaluation was conducted by a sensory test using 10 panelists. The liquid oral composition was used in a normal mouthwash method, and the presence or absence of an unpleasant taste / salty taste felt after spitting out was evaluated according to the following score. The average of the evaluation results of the 10 people was calculated, and the composition that ensured the evaluation of ◎ and ○ according to the following criteria was judged as a composition without an unpleasant taste / salty taste (the unpleasant taste / salty taste was masked).

[0046] (Rating basis) 4 points: No unpleasant taste / saltiness at all 3 points: Almost no unpleasant taste / saltiness 2 points: Slightly unpleasant taste / salty 1 point: Unpleasant taste / salty taste

[0047] (Evaluation Criteria) ◎: 3.5 points or more and 4.0 points or less ○: 3.0 points or more and less than 3.5 points △: 2.0 points or more and less than 3.0 points ×: Less than 2.0 points

[0048] <Evaluation method of dispersibility> 3 L of the liquid oral composition was placed in a stainless steel container, 0.6 g of dipotassium glycyrrhizinate was added, and the mixture was stirred at 200 rpm in an electric stirrer with blades. The time until the mixture was completely dispersed was calculated and the following dispersibility evaluation was performed. ◎ and ○ were considered acceptable.

[0049] (Evaluation Criteria) 4 points: Evenly dispersed in less than 1 minute 3 minutes: Evenly dispersed within 1 minute or more and less than 3 minutes 2 points: Evenly dispersed within 3 minutes or more and less than 5 minutes 1 point: Not evenly dispersed even after more than 5 minutes

[0050] (Judgment Criteria) ◎: 3.5 points or more and 4.0 points or less ○: 3.0 points or more and less than 3.5 points △: 2.0 points or more and less than 3.0 points ×: Less than 2.0 points

[0051] [Table 1] Table 1

[0052] [Table 2] Table 2

[0053] [Table 3] Table 3

[0054] [Table 4] Table 4

[0055] [Table 5] Table 5 [Footnote to table] ○*The flavor derived from the base material (component (C)) appeared.

[0056] While the comparative composition not containing any of the components (A) to (C) was evaluated low in at least any one of the hyperesthesia suppressing effect, unpleasant taste / salty taste reduction, and dispersibility, the compositions of the examples containing the three components were all evaluated well in a well-balanced manner.

[0057] These results show that the liquid oral composition of the present invention can exert a hyperesthesia suppressing effect, mask the salty / unpleasant taste, provide a good feeling during use, and has excellent stability due to good dispersibility of glycyrrhizic acid.

Claims

1. A liquid oral composition, characterized in that contain: Component A: glycyrrhizic acid or its salt, Ingredient B: Inorganic water-soluble potassium salt and Component C: pyrrolidone carboxylate.

2. The liquid oral composition according to claim 1, wherein Component A is one or more selected from the group consisting of sodium salts, potassium salts, and ammonium salts of glycyrrhizic acid.

3. The liquid oral composition according to claim 1 or 2, wherein The component B is one or more selected from potassium nitrate and potassium fluoride.

4. The liquid oral composition according to claim 1 or 2, wherein The component C is one or more selected from pyrrolidone carboxylates, and the pyrrolidone carboxylates are selected from sodium pyrrolidone carboxylate, calcium pyrrolidone carboxylate, magnesium pyrrolidone carboxylate, zinc pyrrolidone carboxylate, and potassium pyrrolidone carboxylate.

5. The liquid oral composition according to claim 1 or 2, wherein The content of the component A is 0.001 to 2 mass %.

6. The liquid oral composition according to claim 1 or 2, wherein The content of the component B is 0.08 to 10.5% by mass.

7. The liquid oral composition according to claim 1 or 2, wherein The content of the component B is 0.1 to 10% by mass.

8. The liquid oral composition according to claim 1 or 2, wherein The content of the component C is 0.08 to 21% by mass as the amount of pyrrolidone carboxylic acid.

9. The liquid oral composition according to claim 1 or 2, wherein The content of the component C is 0.1 to 20% by mass as the amount of pyrrolidone carboxylic acid.

10. The liquid oral composition according to claim 1 or 2, wherein The ratio B / A of the content of the component B to the content of the component A is 0.09 to 10,000.

11. The liquid oral composition according to claim 1 or 2, wherein The ratio B / A of the content of the component B to the content of the component A is 0.1 to 5,000.

12. The liquid oral composition according to claim 1 or 2, wherein The ratio C / B of the content of the component C to the content of the component B is 0.01 to 420.

13. The liquid oral composition according to claim 1 or 2, wherein The ratio C / B of the content of the component C to the content of the component B is 0.01 to 200.

14. The liquid oral composition according to claim 1 or 2, wherein The ratio C / A of the content of the component C to the content of the component A is 0.05 to 10,500.

15. The liquid oral composition according to claim 1 or 2, wherein The ratio C / A of the content of the component C to the content of the component A is 0.1 to 10,000.

Images